Few consumer trends today have the potential to send shockwaves across the entire nation’s economy. A standout exception is Ozempic and other GLP-1 medications, which, over the past few months, have been hailed by some as a sort of “miracle drug” for weight loss. The proliferation of this new class of medications stands to disrupt everything from healthcare to retail, food service, fitness, apparel, and even travel.
Our new Ozempic/GLP-1 Consumer Tracker Series is dedicated to exploring the broad social, cultural, and economic impacts of this emerging class of medications. Through this series, we aim to gain insights into the shifts in user behavior and profiles in order to better understand the market implications. Each month, we will delve deeper into these trends and provide a comprehensive analysis of the market.
THE FIRST REPORT IN THE SERIES IS AVAILABLE FOR PURCHASE NOW. REACH OUT IF YOU WOULD LIKE TO SUBSCRIBE AND RECEIVE ALL 12 REPORTS!